Related Experiment Video
Updated: Jul 15, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
232
Rheumatoid arthritis: the old issue, the new therapeutic approach
Mahnaz Babaahmadi1,2, Behnoosh Tayebi1,2, Nima Makvand Gholipour2
1Department of Applied Cell Sciences, Faculty of Basic Sciences and Advanced Medical Technologies, Royan Institute, ACECR, Tehran, Iran.
Stem Cell Research & Therapy
|September 23, 2023
Summary
Mesenchymal stromal cells (MSCs) show promise for treating rheumatoid arthritis (RA), a chronic autoimmune disease. These cells modulate the immune system, offering a potential new therapy for patients unresponsive to current treatments.
Area of Science:
- Immunology
- Rheumatology
- Cell Therapy
Background:
- Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by joint inflammation and potential disability.
- Current pharmaceutical treatments for RA are limited, with 30-40% of patients showing inadequate response.
- The exact etiology of RA remains unknown, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the mechanisms underlying rheumatoid arthritis (RA).
- To examine the role of cytokines and current medicinal therapies in RA management.
- To discuss the immunomodulatory functions of mesenchymal stromal cells (MSCs) in the context of RA treatment.
Main Methods:
- Review of existing literature on RA pathogenesis.
- Analysis of cytokine involvement in RA.
- Examination of current RA pharmaceutical therapies.
- Exploration of mesenchymal stromal cells (MSCs) and their immunomodulatory properties.
Main Results:
- Mesenchymal stromal cells (MSCs) demonstrate significant potential in modulating the immune system.
- Experimental studies and clinical trials indicate MSCs' efficacy in controlling inflammatory and autoimmune conditions like RA.
- MSCs offer a promising avenue for patients with RA who do not respond to conventional therapies.
Conclusions:
- Understanding MSCs' immune-suppressing mechanisms is crucial for their therapeutic application.
- MSCs represent a promising tool for the treatment of autoimmune diseases, including rheumatoid arthritis.
- Further research into MSC-based therapies could revolutionize RA management.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
11
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
11
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
01:20Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18
01:29Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
01:23Rheumatic Heart Disease I: Introduction
14
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
14
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186